Increased Risk of Cutaneous Immune-Related Adverse Events in Patients Treated With Talimogene Laherparepvec Plus Immune Checkpoint Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study
J Am Acad Dermatol 2023 Jun 01;88(6)1265-1270, BW Leung, G Wan, N Nguyen, H Rashdan, S Zhang, W Chen, S Cohen, GM Boland, RJ Sullivan, RM Fadden, HL Kaufman, SG Kwatra, NR LeBoeuf, YR SemenovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.